CN104520274B - Pfkfb3抑制剂和用作抗癌治疗剂的方法 - Google Patents

Pfkfb3抑制剂和用作抗癌治疗剂的方法 Download PDF

Info

Publication number
CN104520274B
CN104520274B CN201380024610.9A CN201380024610A CN104520274B CN 104520274 B CN104520274 B CN 104520274B CN 201380024610 A CN201380024610 A CN 201380024610A CN 104520274 B CN104520274 B CN 104520274B
Authority
CN
China
Prior art keywords
cancer
pfk
pyridin
quinolin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380024610.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104520274A (zh
Inventor
P·钱德
G·H·塔博斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Cancer Therapeutics LLC
Original Assignee
Advanced Cancer Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cancer Therapeutics LLC filed Critical Advanced Cancer Therapeutics LLC
Priority to CN201610578370.2A priority Critical patent/CN106074368B/zh
Publication of CN104520274A publication Critical patent/CN104520274A/zh
Application granted granted Critical
Publication of CN104520274B publication Critical patent/CN104520274B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380024610.9A 2012-03-29 2013-03-14 Pfkfb3抑制剂和用作抗癌治疗剂的方法 Expired - Fee Related CN104520274B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610578370.2A CN106074368B (zh) 2012-03-29 2013-03-14 Pfkfb3抑制剂和用作抗癌治疗剂的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617073P 2012-03-29 2012-03-29
US61/617,073 2012-03-29
PCT/US2013/031159 WO2013148228A1 (en) 2012-03-29 2013-03-14 Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610578370.2A Division CN106074368B (zh) 2012-03-29 2013-03-14 Pfkfb3抑制剂和用作抗癌治疗剂的方法

Publications (2)

Publication Number Publication Date
CN104520274A CN104520274A (zh) 2015-04-15
CN104520274B true CN104520274B (zh) 2016-08-24

Family

ID=49261041

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610578370.2A Expired - Fee Related CN106074368B (zh) 2012-03-29 2013-03-14 Pfkfb3抑制剂和用作抗癌治疗剂的方法
CN201380024610.9A Expired - Fee Related CN104520274B (zh) 2012-03-29 2013-03-14 Pfkfb3抑制剂和用作抗癌治疗剂的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610578370.2A Expired - Fee Related CN106074368B (zh) 2012-03-29 2013-03-14 Pfkfb3抑制剂和用作抗癌治疗剂的方法

Country Status (9)

Country Link
US (2) US9649305B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2831047B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6075903B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN106074368B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013240340B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2868787A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2629932T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN08886A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013148228A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
CN107635986A (zh) * 2015-05-13 2018-01-26 赛尔维他股份公司 取代的喹喔啉衍生物
WO2016191660A1 (en) * 2015-05-28 2016-12-01 University Of Louisville Research Foundation, Inc. Combinations of pfkfb3 inhibitors and immune checkpoint inhibitors to treat cancer
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
CN109890809A (zh) * 2016-11-08 2019-06-14 默克专利股份公司 作为pfkfb的抑制剂的取代的喹喔啉衍生物
CN109136206B (zh) * 2017-06-15 2021-07-23 厦门大学 Pfkfb3蛋白的第194位酪氨酸的磷酸化及其应用
CN109134434B (zh) * 2017-11-06 2021-02-19 北京大学深圳研究生院 喹啉或喹唑啉类化合物及其制备方法和应用
BR112022002218A2 (pt) * 2019-08-06 2022-06-07 Univ North Carolina Chapel Hill Ligantes com direcionamento a rna, composições dos mesmos e métodos de fabricação e uso dos mesmos
CN111228265A (zh) * 2020-02-10 2020-06-05 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） p38γ抑制剂在制备治疗胰腺癌药物中的应用
KR102344676B1 (ko) 2020-02-12 2021-12-30 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 근적외선 형광 탐침자로서 유효한 신규 화합물 및 이의 제조방법
CN111996247B (zh) * 2020-08-27 2021-09-10 北京大学人民医院 糖酵解抑制剂及其在修复内皮细胞损伤中的应用
CN114617884B (zh) * 2020-12-10 2023-06-02 中国科学院大连化学物理研究所 Pfk-158在制备抗冠状病毒药物中的应用及药物
WO2022245698A1 (en) * 2021-05-16 2022-11-24 Metanoia Bio Inc. Methods and compositions for treating pancreatic and hepatic disease
US20230242558A1 (en) * 2022-01-31 2023-08-03 New Frontier Bio, Inc. Nicotinate and nicotinamide riboside-based compounds and derivatives thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CN1182846C (zh) * 2003-03-14 2005-01-05 南开大学 水溶性抗癌药紫杉醇复合物及其制备方法
CN1554336A (zh) * 2003-12-23 2004-12-15 广州国桥医药研究有限公司 水溶性青蒿素制剂的制备方法
JP4790704B2 (ja) * 2004-04-12 2011-10-12 トレント・ファーマシューティカルズ・リミテッド Ｈｓｐ７０誘発因子としての２−プロペン−１−オン
CN101020060A (zh) * 2007-03-10 2007-08-22 杨喜鸿 恩替卡韦的环糊精包合物及其制备方法和药物应用
EP2488533B1 (en) * 2009-10-13 2014-07-23 Council of Scientific & Industrial Research Imidazothiazole-chalcone derivatives as potential anticancer agents and process for the preparation thereof
CN102000080A (zh) * 2010-09-21 2011-04-06 江苏先声药物研究有限公司 一种喜树碱类化合物的增溶方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth;Brian Clem et al.;《Molecular Cancer Therapeutics》;20080131;第7卷(第1期);110-120 *
Structure-Based Development of Small Molecule PFKFB3;Minsuh Seo et al.;《PLOS ONE》;20110930;第6卷(第9期);1-12 *

Also Published As

Publication number Publication date
IN2014DN08886A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-22
CA2868787A1 (en) 2013-10-03
US20170258783A1 (en) 2017-09-14
CN106074368A (zh) 2016-11-09
US9649305B2 (en) 2017-05-16
AU2013240340B2 (en) 2016-11-10
AU2013240340A1 (en) 2014-10-23
JP6075903B2 (ja) 2017-02-08
ES2629932T3 (es) 2017-08-16
EP2831047A4 (en) 2015-09-02
WO2013148228A1 (en) 2013-10-03
JP2015512398A (ja) 2015-04-27
CN104520274A (zh) 2015-04-15
US10010542B2 (en) 2018-07-03
CN106074368B (zh) 2019-01-22
EP2831047B1 (en) 2017-05-03
EP2831047A1 (en) 2015-02-04
US20150064175A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
CN104520274B (zh) Pfkfb3抑制剂和用作抗癌治疗剂的方法
TWI855000B (zh) Ｓｔｉｎｇ促效化合物
JP2021175757A (ja) 標的化コンジュゲートならびにその粒子及び製剤
US12233128B2 (en) Degraders that target ALK and therapeutic uses thereof
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
KR102255753B1 (ko) 뮤신 관련 질환의 치료
US11185593B2 (en) Alkylating agent for alkylating target with driver oncogene mutation
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
JP2023116507A (ja) がんを処置する組成物及び方法
EP2519518B1 (en) Imatinib dichloroacetate and anti-cancer agent comprising the same
EP2924044A1 (en) Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
WO2013007172A1 (zh) 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
TW202135792A (zh) 治療癌症之方法
US20220288007A1 (en) Platinum Complex Anti-Neoplastic Agents Comprising a Cannabinoid Ligand
WO2019067511A1 (en) MATERIALS AND METHODS USEFUL IN INDUCING THE DEATH OF CANCER CELLS BY METHUOSIS OR AUTOPHAGIA OR A COMBINATION THEREOF
JP2024521824A (ja) マクロライド化合物
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
CN104995201B (zh) 一种治疗肿瘤细胞增生性疾病的铂（ii）类化合物
JP7698252B2 (ja) 治療薬の核酸媒介性送達
CN106659714A (zh) 用于改变生物信号传导的咪唑和噻唑组合物
CN108148097A (zh) 含有吡啶的苯并咪唑类化合物钴配合物及其应用
US20170022215A1 (en) Compounds for Eradicating or Inhibiting Proliferation of Cancer Stem Cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160824

Termination date: 20200314

CF01 Termination of patent right due to non-payment of annual fee